GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SYNBIOTIC SBX.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

0.13

-7.18%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SYNBIOTIC

Its shares trade on XETRA under the ticker SBX.DE. It has been listed since 13 May 2021. In the fiscal year to 31 December 2024, it reported revenue of €14.3m and a net loss of €9.7m. At that date it held total assets of €45.7m and shareholders' equity of €22.9m.

SynBiotic SE operates as a cannabis company, which is engaged in EU-focused buy-and-build investment approach. The company is headquartered in Muenchen, Bayern. The company went IPO on 2021-05-13. Mainly the Company invests in cannabinoid focused ventures and teams.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
13 May 2021
Employees
104

Leadership

Pay as last reported

  • Mr. Sebastian StietzelChairman of the Supervisory Board
  • Mr. Daniel KruseChief Executive Officer
  • Dr. Le Roy DoweyChief Executive Officer of Greenlight Pharmaceutical Ltd
  • Dr. James LindenFounder & Chairman Greenlight Pharmaceutical
  • Mr. Rainer SeilerCo-Founder & Shareholder Cannexo Pharma GmbH
  • Dr. Marlon BraumannMember of the Supervisory Board
  • Mr. Thomas HankeMember of the Supervisory Board

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SynBiotic SE has 104 employees focused on EU cannabis investments in the Health Care sector.
  • The company's buy-and-build strategy targets cannabinoid ventures within the EU market.
  • SynBiotic SE's IPO on 13 May 2021 provided capital for EU-focused growth.

Weaknesses

  • SynBiotic SE operates in a highly regulated EU cannabis market with strict compliance requirements.
  • The company's focus on cannabinoid ventures may limit diversification across other Health Care segments.
  • SynBiotic SE's small employee count of 104 may hinder rapid expansion in the EU market.

Opportunities

  • EU cannabis market growth offers expansion opportunities for SynBiotic SE's cannabinoid ventures.
  • SynBiotic SE can leverage its EU focus to attract investors in the Health Care sector.
  • The company's buy-and-build approach can integrate new ventures in the EU pharmaceutical market.

Threats

  • Regulatory changes in the EU cannabis sector could disrupt SynBiotic SE's operations.
  • Competition from established EU pharmaceutical companies may challenge SynBiotic SE's market position.
  • Economic downturns in the EU could reduce investment in cannabinoid ventures for SynBiotic SE.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.